For decades, RAS proteins have been considered “undruggable”. This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.

Along with this success, significant efforts are now being placed within discovery of drugs that treat a broader range of RAS mutants beyond G12C. The 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit, will shine a spotlight onto pioneering discovery effort targeting the RAS/MAPK pathway, and benchmark the various innovative modalities being harnessed to target RAS mutations beyond G12C, giving you the opportunity to establish and accelerate your drug discovery platform by targeting the RAS/MAPK pathway at every turn.

Join this meeting to hear cutting-edge science and latest data on:

Icon 1

Drugging broader range of RAS isoforms and mutants, to successfully drug all RAS driven cancers in lung and beyond

Icon 2

Advanced screening platforms and tools to guide RAS drug discovery

Icon 3

Identification of target escape routes to further disrupt RAS/MAPK pathway signaling

Icon 4

Emerging discovery pipelines of inhibitors versus degradation strategies targeting the RAS/MAPK pathway-driven cancers

Join 150+ Scientists, Directors and Heads of Drug Discovery, Cancer Biology and Medicinal Chemistry for a deep dive into protein interactions, target activity and engagement as well as optimization of novel chemical staring points to successfully shut down the RAS/MAPK pathway. Download the full event guide

Expert Speakers Include:

Armon Sharei

CEO & Founder

SQZ Biotechnologies

Hanna Budayeva

Principal Scientific Researcher


Hugh Salter

Chief Scientific Officer


Mallika Singh

Vice President, Translational Research

Revolution Medicine

Iris Valtingojer

Group Leader, Oncology Research

Sanofi R&D

Jeff Ecsedy

Chief Scientific Officer

Ikena Oncology

Jeffrey Rothman

Assistant Professor

Columbia University Medical Center & CSO, Founder Oncogenuity

Poulikos Poulikakos

Associate Professor

Icahn School of Medicine at Mount Sinai

Hear What Our Past Attendees Said

25628- 3rd RAS Pathway - Targeted Drug Discovery Summit

Who Attended in 2021

Other Events In The Undruggable Series